News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
621,237 Results
Type
Article (44795)
Company Profile (174)
Press Release (576268)
Multimedia
Podcasts (63)
Webinars (15)
Section
Business (174289)
Career Advice (2571)
Deals (31582)
Drug Delivery (105)
Drug Development (75446)
Employer Resources (153)
FDA (14404)
Job Trends (13801)
News (302123)
Policy (29312)
Tag
Academia (2745)
Academic (1)
Accelerated approval (8)
Adcomms (28)
Allergies (94)
Alliances (46335)
ALS (111)
Alzheimer's disease (1505)
Antibody-drug conjugate (ADC) (163)
Approvals (14388)
Artificial intelligence (330)
Autoimmune disease (30)
Automation (19)
Bankruptcy (330)
Best Places to Work (11185)
BIOSECURE Act (17)
Biosimilars (111)
Biotechnology (124)
Bladder cancer (94)
Brain cancer (35)
Breast cancer (360)
Cancer (2859)
Cardiovascular disease (225)
Career advice (2168)
Career pathing (32)
CAR-T (184)
CDC (34)
Cell therapy (497)
Cervical cancer (20)
Clinical research (62110)
Collaboration (1018)
Company closure (3)
Compensation (570)
Complete response letters (27)
COVID-19 (2577)
CRISPR (61)
C-suite (346)
Cystic fibrosis (103)
Data (2956)
Decentralized trials (2)
Denatured (11)
Depression (72)
Diabetes (338)
Diagnostics (6332)
Digital health (20)
Diversity (8)
Diversity, equity & inclusion (41)
Drug discovery (148)
Drug pricing (130)
Drug shortages (26)
Duchenne muscular dystrophy (122)
Earnings (62974)
Editorial (44)
Employer branding (19)
Employer resources (139)
Events (89301)
Executive appointments (885)
FDA (15988)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (883)
Gene editing (131)
Generative AI (27)
Gene therapy (384)
GLP-1 (800)
Government (4529)
Grass and pollen (6)
Guidances (178)
Healthcare (18181)
HIV (40)
Huntington's disease (30)
IgA nephropathy (43)
Immunology and inflammation (164)
Immuno-oncology (10)
Indications (39)
Infectious disease (2757)
Inflammatory bowel disease (147)
Inflation Reduction Act (10)
Influenza (64)
Intellectual property (116)
Interviews (536)
IPO (14407)
IRA (50)
Job creations (3017)
Job search strategy (1776)
Kidney cancer (15)
Labor market (35)
Layoffs (477)
Leadership (25)
Legal (6444)
Liver cancer (80)
Longevity (10)
Lung cancer (407)
Lymphoma (203)
Machine learning (11)
Management (56)
Manufacturing (379)
MASH (99)
Medical device (11857)
Medtech (11861)
Mergers & acquisitions (17903)
Metabolic disorders (851)
Multiple sclerosis (94)
NASH (23)
Neurodegenerative disease (121)
Neuropsychiatric disorders (38)
Neuroscience (2199)
NextGen: Class of 2025 (6442)
Non-profit (4578)
Now hiring (40)
Obesity (423)
Opinion (239)
Ovarian cancer (99)
Pain (104)
Pancreatic cancer (119)
Parkinson's disease (188)
Partnered (20)
Patents (290)
Patient recruitment (160)
Peanut (48)
People (56053)
Pharmaceutical (35)
Pharmacy benefit managers (17)
Phase I (19280)
Phase II (27329)
Phase III (20623)
Pipeline (1628)
Policy (209)
Postmarket research (2382)
Preclinical (8148)
Press Release (70)
Prostate cancer (139)
Psychedelics (45)
Radiopharmaceuticals (245)
Rare diseases (469)
Real estate (5401)
Recruiting (61)
Regulatory (20811)
Reports (29)
Research institute (2423)
Resumes & cover letters (379)
Rett syndrome (10)
RNA editing (8)
RSV (49)
Schizophrenia (94)
Series A (152)
Series B (99)
Service/supplier (16)
Sickle cell disease (62)
Special edition (15)
Spinal muscular atrophy (152)
Sponsored (34)
Startups (3171)
State (2)
Stomach cancer (15)
Supply chain (74)
Tariffs (49)
The Weekly (51)
Vaccines (761)
Venture capital (50)
Weight loss (260)
Women's health (39)
Worklife (18)
Date
Today (89)
Last 7 days (343)
Last 30 days (1774)
Last 365 days (29421)
2025 (15945)
2024 (33037)
2023 (37319)
2022 (48112)
2021 (52125)
2020 (51016)
2019 (44974)
2018 (34162)
2017 (30176)
2016 (29044)
2015 (33768)
2014 (25622)
2013 (21303)
2012 (22836)
2011 (23897)
2010 (21428)
Location
Africa (794)
Alabama (61)
Alaska (5)
Arizona (175)
Arkansas (13)
Asia (37222)
Australia (7353)
California (6729)
Canada (2231)
China (647)
Colorado (296)
Connecticut (305)
Delaware (190)
Europe (85522)
Florida (1065)
Georgia (218)
Hawaii (2)
Idaho (56)
Illinois (614)
India (27)
Indiana (342)
Iowa (15)
Japan (228)
Kansas (101)
Kentucky (29)
Louisiana (16)
Maine (62)
Maryland (964)
Massachusetts (4922)
Michigan (240)
Minnesota (366)
Mississippi (3)
Missouri (94)
Montana (25)
Nebraska (22)
Nevada (79)
New Hampshire (66)
New Jersey (1932)
New Mexico (28)
New York (1909)
North Carolina (1049)
North Dakota (8)
Northern California (2959)
Ohio (229)
Oklahoma (13)
Oregon (28)
Pennsylvania (1440)
Puerto Rico (18)
Rhode Island (32)
South America (1100)
South Carolina (32)
South Dakota (1)
Southern California (2543)
Tennessee (119)
Texas (1039)
United States (25208)
Utah (216)
Virginia (173)
Washington D.C. (65)
Washington State (583)
West Virginia (4)
Wisconsin (63)
621,237 Results for "sygnature discovery formerly known as sygnature chemical services".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Drug Development
Sygnature Discovery Adopts OpenEye Scientific’s Orion™ Platform to Strengthen Molecular Design Services
OpenEye Scientific and Sygnature Discovery – a world-leading integrated discovery and pre-clinical solutions provider – today announced the adoption of OpenEye’s Orion™ platform to power Sygnature’s computational efforts in molecular design drug discovery solutions.
January 21, 2021
·
4 min read
Press Releases
European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia
July 8, 2025
·
6 min read
Breast cancer
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
Datroway, formerly known as Dato-DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
January 21, 2025
·
2 min read
·
Tristan Manalac
Business
Sygnature Discovery strengthens DMPK team
Sygnature Discovery has further strengthened its DMPK (drug metabolism and pharmacokinetics) capabilities, with the addition of new senior scientists to the management team.
January 17, 2020
·
2 min read
Deals
Sygnature Discovery invests in high-throughput screening capability
Sygnature Discovery has added in-house high-throughput screening (HTS) to its range of drug discovery services.
November 4, 2019
·
2 min read
Press Releases
Axcelead DDP Enters into Drug Discovery Service Agreement with Astellas for Targeted Protein Degraders
December 26, 2024
·
1 min read
Press Releases
Parabilis Medicines™ – Formerly FogPharma – Announces New Company Name and Unveils AI- and Physics-Based Discovery Platform
October 28, 2024
·
3 min read
Press Releases
Celltrion’s Remdantry™, previously known as Inflectra®, will be available in Canada as of April 1, 2025
March 27, 2025
·
3 min read
Business
Sygnature Discovery moves US base to Kendall Square
Sygnature Discovery, the leading independent drug discovery and pre-clinical services company, has announced its US office has moved.
September 15, 2019
·
2 min read
1 of 62,124
Next
